摘要
目的评价Graves甲亢(甲亢)伴中性粒细胞减少(粒细胞减少)患者的临床特点、^(131)I治疗的效果及对粒系造血的影响。方法回顾性分析^(131)I治疗的甲亢患者144例,其中42例为甲亢自身致粒细胞减少患者(HT组),52例为抗甲状腺药物(ATD)治疗后出现粒细胞减少患者(ATD组),另50例为粒细胞正常的患者(对照组)。分析和比较三组的临床特点、^(131)I治疗甲亢的疗效及^(131)I治疗后粒细胞计数的变化。结果HT组和ATD组均以轻度粒细胞减少更常见。HT组、ATD组和对照组的甲亢治愈率分别为80.95%、84.62%、84.00%,差异无统计学意义。与治疗前相比,三组患者^(131)I治疗完成后2~4周粒细胞计数均增高(P<0.05);HT组和ATD组粒细胞恢复率分别为61.90%、84.62%,ATD组恢复率较高,差异有统计学意义(P<0.05)。结论甲亢自身或ATD治疗导致粒细胞减少的甲亢患者均以轻度粒细胞减少多见,规范的^(131)I治疗甲亢伴粒细胞减少是安全、有效的。
Objective To analyze the clinical features,the efficacy of ^(131)I therapy and its effect on granulopoiesis in Graves′hyperthyroidism(hyperthyroidism)patients with neutropenia.Methods 144 hyperthyroidism patients were retrospectively studied after ^(131)I therapy,among which 42 cases(HT group)accompanied neutropenia due to hyperthyroidism itself,52 cases(ATD group)appeared neutropenia after anti-thyroid drug(ATD)treatment,and the remaining 50 cases(control group)were hyperthyroidism patients with normal neutrophil count.The clinical features,the efficacy of ^(131)I treatment for hyperthyroidism and the change of neutrophil count after ^(131)I treatmentwere analyzed and compared in three groups.Results Mild neutropenia was commoner in both the HT group and the ATD group.The curative rate of hyperthyroidism in the HT group,the ATD group and the control group were 80.95%,84.62%and 84.00%,respectively.There was no significant difference in the efficacy of ^(131)I therapy among the three groups.Compared with the baseline value before treatment,neutrophil count increased in all three groups 2-4 weeks after ^(131)I treatment(all P<0.05).The neutrophil recovery rates of the HT group and the ATD group were 61.90%and 84.62%,respectively.The ATD group had a higher recovery rate(P<0.05).Conclusion Mild neutropenia is commoner in hyperthyroidism patients with neutropenia due to either hyperthyroidism itself or ATD treatment.Normative ^(131)I treatment for hyperthyroidism patients with neutropenia is safe and effective.
作者
姚晓波
肖林林
卞岍雨
罗玲玲
张然
夏俊勇
叶山东
Yao Xiaobo;Xiao Linlin;Bian Qianyu;Luo Lingling;Zhang Ran;Xia Junyong;Ye Shandong(Dept of Nuclear Medicine,The First Affiliated Hospital of USTC(Anhui Provincial Hospital),Hefei 230001;Dept of Endocrinology,The First Affiliated Hospital of USTC(Anhui Provincial Hospital),Hefei 230001)
出处
《安徽医科大学学报》
CAS
北大核心
2022年第5期823-827,共5页
Acta Universitatis Medicinalis Anhui
基金
安徽省中央引导地方科技发展专项(编号:2017070802D147)。
